In July 2002, Aranesp was for the treatment of for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies. Since its introduction in 2001, more than 1.7 million CKD patients with anemia have received treatment with Aranesp.. Aranesp was by the U.S. Food and Drug Administration in September 2001, well known for the treatment of anemia associated with chronic renal failure , also known as chronic kidney disease (CKD ,, not for patients on dialysis and patients dialysis.
About AranespAmgen revolutionized the treatment of anemia associated with the development of epoetin alfa, recombinant erythropoietin . Building on this heritage, Amgen developed Aranesp, a unique erythropoiesis-stimulating protein that can be dosed less frequently.About which Public Library of ScienceThe Public Library of Science is non-profit organization of physicians and scientists committed to the world of scientific and medical literature a freely accessible public resource. Are, and continue to do, a major contribution to NHS with respect to providing services, testing and research, and development of operational.